论文部分内容阅读
Despite recent progress in our understanding of cancer biology and in many areas of cancer treatment,the successrate for cancer therapy remains dismal.Immunotherapy for cancer has long been an exciting field for many cancerresearchers due to the possibility to mobilize the body’s own immune system to eradicate cancer not only locallybut also systemically.Since its initial discovery,cytokine-based immunotherapy has been vigorously andextensively investigated for cancer treatment due to the perception of it as a relatively easily purifiable,injectableform of cancer treatment agent.However,so far most cytokine-based therapy trials have fallen short ofexpectations.One of main obstacles is the difficulty to achieve therapeutically relevant dosage in patients withoutgenerating excessive normal tissue toxicity.The emergence of novel gene therapy approach to deliver therapeuticcytokine to tumors locally generated great excitement since it has the potential of generating sustained high localconcentration of immunostimulatory cytokine without raising the systemic levels of the cytokines,which isresponsible for most of the observed toxicity.In this review,we will attempt to provide an overview of the field anddiscuss some of the problems associated with cytokine-based immuno-gene therapy and potential solutions.Cellular & Molecular Immunology.2005;2(2):81-91.
Despite recent progress in our understanding of cancer biology and in many areas of cancer treatment, the successrate for cancer therapy remains dismal.Immunotherapy for cancer has long been an exciting field for many cancerresearchers due to the possibility to mobilize the body’s own immune system to eradicate cancer not only locallybut also systematically .ince its initial discovery, cytokine-based immunotherapy has been vigorously an investigatively for investigated treatment of cancer due to the perception of it as a relatively easy purifiable, injectableform of cancer treatment agent. Host, so far most most cytokine-based therapy trials have fallen short ofexpectations. One of the main obstacles is the difficulty to achieve therapeutically relevant dosage in patients withoutgenerating excessive normal tissue toxicity. emergence of novel gene therapy approach to deliver therapeuticcytokine to tumors locally generated great excitement since it has the potential of generating sustained high localcon centration of immunostimulatory cytokine without raising the systemic levels of the cytokines, which isresponsible for most of the observed toxicity. In this review, we will attempt to provide an overview of the field and dysfuse some of the problems associated with cytokine-based immuno-gene therapy and potential solutions. Cellular & Molecular Immunology. 2005; 2 (2): 81-91.